Hollander David

CMO & Global Therapeutics Lead at Revance Therapeutics, Inc.

Sold, on record
$16k
Dollars the filings state
Form 4 sales
1
Latest Nov 18, 2024
Form 144 notices
0
Proposed sales
Companies
1
Filed as an executive or holder

Companies

Sales by reason

0
Routine
0
Plan not stated
1
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, every sale on record.

Sales chart range

Timeline

  1. Nov 18, 2024No plan

    Revance Therapeutics, Inc.

    Sold 3.6% of their holdings

    $16k3,908 shares at $4.17

    Filed Nov 19, 2024Form 4

1 of 1

Every transaction

Every transaction on a Form 4 or Form 5 by Hollander David
TradedFiledStockRoleWhatAmountPriceValueHeld afterSource
Sep 1, 2026Sep 3, 2026MANEChief R&D OfficerAwardedStock Option (Right to Buy)19,30019,300SEC
Sep 1, 2026Sep 3, 2026MANEChief R&D OfficerAwarded9,6509,650SEC
Jun 10, 2026Jun 12, 2026KPRXDirectorAwardedStock Option (right to buy)25,00025,000SEC
Apr 1, 2025Apr 2, 2025KPRXDirectorAwardedStock Option (right to buy)20,00020,000SEC
Feb 6, 2025Feb 6, 2025Revance Therapeutics, Inc.CMO & Global Therapeutics LeadReturned to the company95,2120SEC
Feb 4, 2025Feb 6, 2025Revance Therapeutics, Inc.CMO & Global Therapeutics LeadTendered9,733$3.65$36k95,212SEC
Nov 18, 2024Nov 19, 2024Revance Therapeutics, Inc.CMO & Global Therapeutics LeadSold3,908$4.17$16k104,945SEC
Jul 1, 2024Jul 3, 2024KPRXDirectorAwardedStock Option (right to buy)1,7781,778SEC
Mar 3, 2023Mar 7, 2023KPRXDirectorAwardedStock Option (right to buy)8,0008,000SEC
Feb 4, 2022Feb 8, 2022AERIE PHARMACEUTICALS INCChief R&D OfficerWithheld for tax927$7.05$7k30,749SEC
Feb 1, 2022Feb 3, 2022KPRXDirectorAwardedStock Option (right to buy)9,0005,000SEC
Nov 11, 2021Nov 15, 2021AERIE PHARMACEUTICALS INCChief R&D OfficerWithheld for tax2,162$12.06$26k31,676SEC
Feb 4, 2021Feb 8, 2021AERIE PHARMACEUTICALS INCChief R&D OfficerAwardedStock option (right to buy)50,00050,000SEC
Feb 4, 2021Feb 8, 2021AERIE PHARMACEUTICALS INCChief R&D OfficerAwarded11,00033,838SEC
Nov 11, 2020Nov 12, 2020AERIE PHARMACEUTICALS INCChief R&D OfficerWithheld for tax2,162$13.05$28k22,838SEC
Nov 11, 2019Nov 13, 2019AERIE PHARMACEUTICALS INCChief R&D OfficerAwardedStock Option (right to buy)110,000110,000SEC
Nov 11, 2019Nov 13, 2019AERIE PHARMACEUTICALS INCChief R&D OfficerAwarded25,00025,000SEC

Sales and notices (1)

Form 144 notices and Form 4 sales by Hollander David
Source
Nov 18, 2024Nov 19, 2024Revance Therapeutics, Inc.CMO & Global Therapeutics LeadForm 4 sale3,908$16k3.6%No planSEC